fashion -WSS

fashion

author：comprehensive 2025-09-06 03:53:03 - browse：527

Johnson & Johnson sign — MARK RALSTON/AFP via Getty Images

WASHINGTON — Pharmaceutical giant Johnson & Johnson on Tuesday became the third drugmaker to sue the Biden administration over its new Medicare drug price negotiation program.

J&J joins a flurry of litigation challenging the Medicare drug price negotiation program, which is set to start this fall. Merck, Bristol Myers Squibb, the brand-drug lobby PhRMA, and the U.S. Chamber of Commerce have also filed suit. The negotiated prices would go into effect in 2026.

The company argued that it is entitled to sue because its blockbuster blood thinner drug Xarelto may be up for negotiation in the first round of ten drugs Medicare will examine, but that list is not set to be announced officially until Sept. 1.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Stanford president to resign after investigation of research

focus

WSS

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Stanford president to resign after investigation of research

Why medical students are struggling with mental health

World's first CRISPR

Anthos stroke drug appears safer than common blood thinner

Man who had jail sentence commuted by Trump arrested again

focus

fashion

hotspot

Walensky prepares to leave CDC — and Congress — behind

Poor hospice wound care hurts patients and families

New air purifier tech could be key to improving indoor air quality

Man who had jail sentence commuted by Trump arrested again

Continuity nursing helped my family in our darkest PICU moments

Congress must reauthorize a committee to support older Americans

Sports medicine is finally prioritizing gender equality

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

23andMe had bad news about my health. I wish a person had delivered it

Medical experts are missing from AI regulatory conversations

focus

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

Medical experts are missing from AI regulatory conversations

Anthos stroke drug appears safer than common blood thinner

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Medical experts are missing from AI regulatory conversations

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

focus

leisure time

focus

focus